MAPT and Alzheimer disease: Preliminary data for another agent from this group, F-18 TKH5105, an arylquinoline derivative, have shown that this probe selectively binds to pathological PHF tau-deposition in living patients with AD, and may differentiate diseased brains from healthy controls.